Literature DB >> 24844432

[The relevance of PET/CT for the surgical management of neuroendocrine neoplasms].

M Hommann1, D Kaemmerer, D Hörsch, H R Kulkarni, F Robiller, R P Baum.   

Abstract

Neuroendocrine neoplasms (NEN) are rare malignancies with a wide spectrum of metastatic potential which originate from the endocrine cells of the body and express somatostatin receptors. The (68)gallium somatostatin receptor positron emission tomography-computed tomography (PET/CT) technique is the most sensitive method of assessment of well-differentiated NENs and for the detection of cancer of unknown primary (CUP syndrome) NENs. Imaging with 18F-fluorodeoxyglucose (18F-FDG PET/CT) is indicated in poorly differentiated neuroendocrine carcinomas. The receptor-dependent imaging of NENs has a decisive impact on further management.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24844432     DOI： 10.1007/s00104-013-2671-0

Source DB:  PubMed          Journal:  Chirurg        ISSN： 0009-4722            Impact factor:   0.955


  17 in total

Review 1.  Current treatment options for neuroendocrine tumors.

Authors:  D Hörsch; P Grabowski; C P Schneider; A Petrovitch; D Kaemmerer; M Hommann; R P Baum
Journal:  Drugs Today (Barc)       Date:  2011-10       Impact factor: 2.245

2.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.

Authors:  Massimo Falconi; Detlef Klaus Bartsch; Barbro Eriksson; Günter Klöppel; José M Lopes; Juan M O'Connor; Ramón Salazar; Babs G Taal; Marie Pierre Vullierme; Dermot O'Toole
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

Review 3.  The radionuclide molecular imaging and therapy of neuroendocrine tumors.

Authors:  Shuren Li; Mohsen Beheshti
Journal:  Curr Cancer Drug Targets       Date:  2005-03       Impact factor: 3.428

4.  Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.

Authors:  Daniel Kaemmerer; Luisa Peter; Amelie Lupp; Stefan Schulz; Jörg Sänger; Vikas Prasad; Harshad Kulkarni; Sven-Petter Haugvik; Merten Hommann; Richard Paul Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-31       Impact factor: 9.236

Review 5.  Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Casper H J van Eijck; Boen L Kam; Martijn van Essen; Jaap J M Teunissen; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2010-03       Impact factor: 4.446

6.  Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?

Authors:  Marius E Mayerhoefer; Matthias Schuetz; Silvia Magnaldi; Michael Weber; Siegfried Trattnig; Georgios Karanikas
Journal:  Eur Radiol       Date:  2011-11-12       Impact factor: 5.315

7.  Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.

Authors:  E P Krenning; W H Bakker; W A Breeman; J W Koper; P P Kooij; L Ausema; J S Lameris; J C Reubi; S W Lamberts
Journal:  Lancet       Date:  1989-02-04       Impact factor: 79.321

8.  Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.

Authors:  Henning Jann; Stephanie Roll; Anne Couvelard; Olivia Hentic; Marianne Pavel; Jacqueline Müller-Nordhorn; Martin Koch; Christoph Röcken; Guido Rindi; Philippe Ruszniewski; Bertram Wiedenmann; Ulrich-Frank Pape
Journal:  Cancer       Date:  2011-01-18       Impact factor: 6.860

Review 9.  Gallium-68 PET: a new frontier in receptor cancer imaging.

Authors:  A Al-Nahhas; Z Win; T Szyszko; A Singh; C Nanni; S Fanti; D Rubello
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

10.  Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs).

Authors:  Kjell Oberg
Journal:  Theranostics       Date:  2012-05-08       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.